Hely Shah1, Julian Surujballi2, Arif Ali Awan2, Brian Hutton3, Angel Arnaout4, Risa Shorr5, Lisa Vandermeer6, Mashari Jemaan Alzahrani2, Mark Clemons7,8,9. 1. Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada. 2. Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, Canada. 3. The University of Ottawa, School of Epidemiology and Public Health, and Ottawa Hospital Research Institute, Ottawa, ON, Canada. 4. Department of Surgery, The Ottawa Hospital, Ottawa, ON, Canada. 5. The Ottawa Hospital, Ottawa, ON, Canada. 6. Ottawa Hospital Research Institute, Ottawa, ON, Canada. 7. Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada. mclemons@toh.ca. 8. Division of Medical Oncology, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, ON, Canada. mclemons@toh.ca. 9. The University of Ottawa, School of Epidemiology and Public Health, and Ottawa Hospital Research Institute, Ottawa, ON, Canada. mclemons@toh.ca.
Abstract
PURPOSE: Choosing Wisely (CW)® was created by the American Board of Internal Medicine (ABIM) to promote patient-physician conversations about unnecessary medical interventions. Similarly, other countries created their own panels of experts called "CW® campaigns" which review recommendations submitted by that country's oncology societies. We performed a scoping review to consolidate CW® recommendations from different groups with respect to breast cancer care. METHODS: A systematic search of Medline and Embase was designed by an information specialist for publications presenting CW® recommendations for breast cancer care practices from 2011-2020. We also reviewed the websites of all CW® campaigns and reference sections of each CW® recommendation. Two reviewers independently screened studies for inclusion and performed data extraction. Findings were summarized narratively. RESULTS: Review of ABIM CW® recommendations showed 19 breast cancer-related recommendations pertaining to; screening (n = 4), radiological staging (n = 2), treatment (n = 10), surveillance (n = 2), and miscellaneous (genetic testing; n = 1). Of 22 countries with CW® campaigns, 10 published recommendations for breast cancer. Over half (57%) of recommendations were supported by more than one country. No recommendations were refuted between campaigns. Two campaigns developed 3 novel recommendations on new topics, including chemotherapy in ductal carcinoma in situ (Italy) and comparison of screening imaging modalities (Portugal). CONCLUSIONS: CW® recommendations focus on reducing overutilization of investigations and treatments. There was a high rate of consensus between different CW® campaigns. As health care systems globally move attention to reduce low-value care, further studies are required to address adherence to these current recommendations and develop new recommendations.
PURPOSE: Choosing Wisely (CW)® was created by the American Board of Internal Medicine (ABIM) to promote patient-physician conversations about unnecessary medical interventions. Similarly, other countries created their own panels of experts called "CW® campaigns" which review recommendations submitted by that country's oncology societies. We performed a scoping review to consolidate CW® recommendations from different groups with respect to breast cancer care. METHODS: A systematic search of Medline and Embase was designed by an information specialist for publications presenting CW® recommendations for breast cancer care practices from 2011-2020. We also reviewed the websites of all CW® campaigns and reference sections of each CW® recommendation. Two reviewers independently screened studies for inclusion and performed data extraction. Findings were summarized narratively. RESULTS: Review of ABIM CW® recommendations showed 19 breast cancer-related recommendations pertaining to; screening (n = 4), radiological staging (n = 2), treatment (n = 10), surveillance (n = 2), and miscellaneous (genetic testing; n = 1). Of 22 countries with CW® campaigns, 10 published recommendations for breast cancer. Over half (57%) of recommendations were supported by more than one country. No recommendations were refuted between campaigns. Two campaigns developed 3 novel recommendations on new topics, including chemotherapy in ductal carcinoma in situ (Italy) and comparison of screening imaging modalities (Portugal). CONCLUSIONS: CW® recommendations focus on reducing overutilization of investigations and treatments. There was a high rate of consensus between different CW® campaigns. As health care systems globally move attention to reduce low-value care, further studies are required to address adherence to these current recommendations and develop new recommendations.
Authors: Esteban Calderon; Christopher Webb; Heidi E Kosiorek; M D Richard J Gray; Patricia Cronin; Karen Anderson; Donald Northfelt; Ann McCullough; Idris Tolgay Ocal; Barbara Pockaj Journal: Am J Surg Date: 2019-08-10 Impact factor: 2.565
Authors: C S Pramesh; Harit Chaturvedi; Vijay Anand Reddy; Tapan Saikia; Sushmita Ghoshal; Mrinalini Pandit; K Govind Babu; K V Ganpathy; Dhairyasheel Savant; Gunita Mitera; Richard Sullivan; Christopher M Booth Journal: Lancet Oncol Date: 2019-03-08 Impact factor: 41.316
Authors: Marissa K Srour; Minna Lee; Sarah Walcott-Sapp; Michael Luu; Alice Chung; Armando E Giuliano; Farin Amersi Journal: Ann Surg Oncol Date: 2019-07-24 Impact factor: 5.344
Authors: Kelsey Corrigan; Leonid Aksenov; Alexandra Paul; Banafsheh Sharif-Askary; Sarvesh Agarwal; Arif Kamal Journal: Am J Med Qual Date: 2018-10-20 Impact factor: 1.852
Authors: David Moher; Larissa Shamseer; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart Journal: Syst Rev Date: 2015-01-01
Authors: Lia M Halasz; Shilpen A Patel; Jean A McDougall; Catherine Fedorenko; Qin Sun; Bernardo H L Goulart; Joshua A Roth Journal: PLoS One Date: 2019-09-30 Impact factor: 3.240